Year-end Sale % OFF 
Abstract
ABSTRACT Background Mitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events. Methods A retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane. Results Mitotane toxicity was present in all patients (100%). Two (7.7%) patients developed 1–3 adverse events, 15 (57.7%) experienced 4–6 adverse events and 9 (34.6%) patients had more than 6 adverse events. Two (7.7%) patients discontinued mitotane due to adverse events. Conclusion Careful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
